Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Ardelyx Inc
Nieuws
Ardelyx Inc
ARDX
NAS
: ARDX
| ISIN: US0396971071
8/06/2023
3,930 USD
(+4,52%)
(+4,52%)
8/06/2023
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
2 februari 2023 ·
Ardelyx, Inc. Reports Employment Inducement Grants
· Persbericht
29 december 2022 ·
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
· Persbericht
23 december 2022 ·
Ardelyx, Inc. Reports Employment Inducement Grants
· Persbericht
17 december 2022 ·
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
· Persbericht
22 november 2022 ·
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
· Persbericht
17 november 2022 ·
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
· Persbericht
16 november 2022 ·
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
· Persbericht
4 november 2022 ·
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
· Persbericht
3 november 2022 ·
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
· Persbericht
3 november 2022 ·
Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
· Persbericht
2 november 2022 ·
Ardelyx, Inc. Reports Employment Inducement Grants
· Persbericht
31 oktober 2022 ·
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
· Persbericht
27 oktober 2022 ·
Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
· Persbericht
24 oktober 2022 ·
Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
· Persbericht
20 oktober 2022 ·
Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022
· Persbericht
30 september 2022 ·
Ardelyx, Inc. Reports Employment Inducement Grants
· Persbericht
6 september 2022 ·
Ardelyx to Participate in Upcoming Investor Conferences
· Persbericht
4 augustus 2022 ·
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
· Persbericht
2 augustus 2022 ·
Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
· Persbericht
28 juli 2022 ·
Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe